HC Wainwright Issues Pessimistic Forecast for SNTI Earnings

Senti Biosciences, Inc. (NASDAQ:SNTI) – Investment analysts at HC Wainwright lowered their Q2 2026 earnings per share estimates for shares of Senti Biosciences in a note issued to investors on Friday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.33) per share for the quarter, down from their previous forecast of ($0.14). The consensus estimate for Senti Biosciences’ current full-year earnings is ($1.03) per share. HC Wainwright also issued estimates for Senti Biosciences’ Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at ($0.72) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at ($0.20) EPS.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.22. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.

Several other equities research analysts have also recently weighed in on the company. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Tuesday, April 21st. Finally, Chardan Capital upped their price objective on Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.75.

Senti Biosciences Trading Down 6.9%

Shares of SNTI stock opened at $0.94 on Tuesday. Senti Biosciences has a twelve month low of $0.77 and a twelve month high of $3.88. The stock has a market capitalization of $29.28 million, a price-to-earnings ratio of -0.49 and a beta of 2.09. The stock has a fifty day simple moving average of $0.95 and a two-hundred day simple moving average of $1.20.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares during the period. Armistice Capital LLC purchased a new position in shares of Senti Biosciences in the second quarter valued at approximately $1,883,000. Citadel Advisors LLC purchased a new position in shares of Senti Biosciences in the third quarter valued at approximately $117,000. Jane Street Group LLC purchased a new position in shares of Senti Biosciences in the fourth quarter valued at approximately $40,000. Finally, Virtu Financial LLC purchased a new position in shares of Senti Biosciences in the fourth quarter valued at approximately $46,000. 25.70% of the stock is owned by institutional investors and hedge funds.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.